Time course of bleomycin‐induced lung fibrosis
Open accessAbstract
Summary.: Intratracheal instillation (IT) of bleomycin is a widely used experimental model for lung fibrosis. In this study we describe the time‐course of bleomycin‐induced lung fibrosis in mice using computer‐assisted morphometry. C57Bl/6J mice were treated with a single IT dose of bleomycin or control saline. Animals were killed 3, 6, 14 and 21 days post‐IT. Lung injury was evaluated by analysis of bronchoalveolar lavage (BAL) fluid, hydroxyproline concentration in the lung, routine light microscopic examination resulting in a semiquantitative morphological index (SMI) of lung injury, and quantitative morphological measurements (fibrosis fraction and alveolar wall area fraction) aided by optimas image analysis software. Changes in BAL fluid attributed to bleomycin treatment include increased total cell count (days 14 and 21), and increased percentage of neutrophils (days 3 and 6) followed by a sustained increase in lymphocytes (days 6, 14 and 21). Hydroxyproline levels increased in bleomycin‐treated mice on days 14 and 21. Median SMI grades were significantly elevated on days 3, 14 and 21. Computer‐assisted morphometry demonstrated a 3‐fold increase in fibrosis fraction and a 1.3‐fold increase in wall area fraction in bleomycin‐treated mice on day 14, with no further increase on day 21. These data also demonstrate that the most suitable time point for assessing lung fibrosis in this model is 14 days after IT instillation of bleomycin, based on the observation that at 14 days the animals developed extensive fibrosis, but had less variability in the fibrotic response and lower mortality than later at 21 days. Computer‐assisted morphometry provides objective and quantitative measurements that are a useful tool for the evaluation of bleomycin‐induced lung injury.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Bleomycin-induced lung injury in mice recapitulates critical features of human IPF.
“Aerosolized intratracheal instillation of the chemotherapeutic agent bleomycin induces lung fibrosis in mice and recapitulates critical features of human IPF15.”
From Cellular senescence mediates fibrotic pulmonary disease (2017) · cites this paper as [15]
Cited by
Sorted by citations
Cellular senescence mediates fibrotic pulmonary disease
Schafer, M. J., White, T. A., Iijima, K., Haak, A. J., Ligresti, G., Atkinson, E. J., Oberg, A. L., Birch, J., Salmonowicz, H., Zhu, Y., et al. (2017) · Nature Communications · doi:10.1038/ncomms14532 · Cited by 1,613 · see citing works
Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance
Hecker, L., Logsdon, N. J., Kurundkar, D., Kurundkar, A., Bernard, K., Hock, T., Meldrum, E., Sanders, Y. Y., & Thannickal, V. J. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008182 · Cited by 686 · see citing works
Wollin, L., Maillet, I., Quesniaux, V., Holweg, A., & Ryffel, B. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.208223 · Cited by 633 · see citing works
Human Umbilical Cord Mesenchymal Stem Cells Reduce Fibrosis of Bleomycin-Induced Lung Injury
Moodley, Y., Atienza, D., Manuelpillai, U., Samuel, C. S., Tchongue, J., Ilancheran, S., Boyd, R., & Trounson, A. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080629 · Cited by 356 · see citing works
Yang, D., Chen, X., Wang, J., Lou, Q., Lou, Y., Li, L., Wang, H., Chen, J., Wu, M., Song, X., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.02.001 · Cited by 250 · see citing works
Activation of JUN in fibroblasts promotes pro-fibrotic programme and modulates protective immunity
Cui, L., Chen, S.-Y., Lerbs, T., Lee, J.-W., Domizi, P., Gordon, S., Kim, Y.-H., Nolan, G., Betancur, P., & Wernig, G. (2020) · Nature Communications · doi:10.1038/s41467-020-16466-4 · Cited by 153 · see citing works
Nanoparticle targeting of de novo profibrotic macrophages mitigates lung fibrosis
Singh, A., Chakraborty, S., Wong, S. W., Hefner, N. A., Stuart, A., Qadir, A. S., Mukhopadhyay, A., Bachmaier, K., Shin, J.-W., Rehman, J., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2121098119 · Cited by 107 · see citing works
Nanoengineered mesenchymal stem cell therapy for pulmonary fibrosis in young and aged mice
Han, M.-M., He, X.-Y., Tang, L., Qi, L., Yang, M.-Y., Wang, Y., Xing, L., Jeong, J.-H., & Jiang, H.-L. (2023) · Science Advances · doi:10.1126/sciadv.adg5358 · Cited by 86 · see citing works
Li, Q., Cheng, Y., Zhang, Z., Bi, Z., Ma, X., Wei, Y., & Wei, X. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.1036 · Cited by 77 · see citing works
A novel phosphodiesterase 4 inhibitor, AA6216, reduces macrophage activity and fibrosis in the lung
Matsuhira, T., Nishiyama, O., Tabata, Y., Kaji, C., Kubota-Ishida, N., Chiba, Y., Sano, H., Iwanaga, T., & Tohda, Y. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173508 · Cited by 41 · see citing works
- Authors
- Izbicki, G., Segel, M. J., Christensen, T. G., Conner, M. W., & Breuer, R.
- Affiliations
- Hebrew University of Jerusalem (IL)
- Boston University (US)
- Corresponding author
- Breuer, R.
- Venue
- International Journal of Experimental Pathology
- Publisher
- Wiley
- Published
- 2002-06
- Volume
- 83
- Issue
- 3
- Pages
- 111-119
- ISSN
- 0959-9673 (ISSN-L)
- 1365-2613
- PMC
- PMC2517673
- OpenAlex
- W1879089985
- Cited by
- 447
- References
- 0
- Citations by year
- 2026: 20 · 2025: 31 · 2024: 34 · 2023: 37 · 2022: 29 · 2021: 30 · 2020: 29 · 2019: 19 · 2018: 15 · 2017: 26 · 2016: 20 · 2015: 18 · 2014: 17 · 2013: 15 · 2012: 12
- FWCI
- 4.94
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- International Journal of Experimental Pathology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- School of Medicine, Boston University
- Hebrew University of Jerusalem
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- bleomycin, pulmonary fibrosis, bleomycin-induced lung injury, intratracheal instillation, computer-assisted morphometry, bronchoalveolar lavage, hydroxyproline, neutrophils, lymphocytes, mouse model
- MeSH terms
- Animals, Antimetabolites, Antineoplastic, Bleomycin, Bronchoalveolar Lavage Fluid, Cell Count, Hydroxyproline, Image Processing, Computer-Assisted, Instillation, Drug, Lung, Male, Mice, Inbred C57BL, Pulmonary Fibrosis, Time Factors, Models, Animal, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review